ClinicalTrials.gg
Not yet recruitingNCT07672340Care BurdenUpdated Nov 2, 2026

Care Burden And Qualıty of Lıfe

An interventional study of Health Promotion Behavior Education in Caregiver Burden, Quality of Life and Public Health, sponsored by Aydin Adnan Menderes University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Aydin Adnan Menderes University · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial will be conducted to examine the effect of a multidimensional training program, to be implemented by a public health nurse, on the care burden and quality of life of primary caregivers of patients aged 65 and older.

02

Conditions studied

  • Caregiver Burden
  • Quality of Life
  • Public Health

Browse trials for

03

In context

Caregiver Burden

503 studies on the registry are indexed under Caregiver Burden; 166 are open to participants now.

This study's planned enrollment of 78 is close to the median of 73 across 404 interventional studies indexed under Caregiver Burden.

Browse Caregiver Burden studies →

Lead sponsor

Aydin Adnan Menderes University is the lead sponsor of 243 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Be willing to participate in the study

  • Be literate
  • Have registered with a home health care unit
  • Have been responsible for the care of a relative aged 65 or older for at least one month
  • Score at least 21 on the Zarit Caregiver Burden Scale

Exclusion criteria

Exclusion Criteria:

    • Having severe reading comprehension difficulties

      • Having severe hearing difficulties
      • Having been diagnosed with a psychiatric disorder (schizophrenia, bipolar disorder, or anxiety disorder)
      • Failing to complete the data collection instruments used in the study
      • Failing to attend at least two training sessions
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • No intervention
    Control group

    The control group continued to receive the routine care

  • Experimental
    Structured education

    Caregivers in the intervention groups will undergo a four-session intervention program in addition to the routine care provided by other caregivers. The training, which is planned to last four weeks and includes activities aimed at reducing the impact of the caregiving role on caregivers, involves the delivery of a training program designed to improve caregivers' adaptation to their caregiving roles.

    Behavioral: Health Promotion Behavior Education

Interventions

  • BehavioralHealth Promotion Behavior Education

    Personal hygiene, hand hygiene, Musculoskeletal system, body mechanics, relaxation exercises, the importance of physical activity, Proper and healthy nutrition, foods to increase and decrease consumption of, food safety and hygiene, Sleep health, sleep hygiene, the importance of sleep in human life, sleep quality, sleep duration, and factors affecting sleep, Early detection methods, adult immunization, rational use of medications, Safe environment and home accidents.

    Also known as: Social health dimension, Physical health, Psychological health dimension, Emotional health dimension

06

What researchers measure

Primary outcomes

  1. Before intervention caregiving burden

    The Caregiver Burden Scale will be used to assess the stress experienced by caregivers. It consists of 22 statements that evaluate the impact of caregiving on the caregiver's life and uses a Likert-type scale. The scale's highest score is 88, and the lowest is 0. Higher scores are associated with an increased caregiving burden.

    Time frame: Before intervention

  2. After intervention caregiving burden

    The Caregiver Burden Scale will be used to assess the stress experienced by caregivers. It consists of 22 statements that assess the impact of caregiving on the caregiver's life and uses a Likert-type scale. The maximum score on the scale is 88, and the minimum is 0. Higher scores are associated with increased caregiving burden.

    Time frame: 1 week after intervention

Secondary outcomes

  1. Before intervention

    Pre-Intervention Life Satisfaction This scale was developed to assess how an individual perceives their quality of life. The scale was created by condensing the World Health Organization Quality of Life Assessment scale to 26 questions. During the validity studies of the Turkish version, a national question was added, bringing the total number of questions to 27, and the Turkish version was finalized. Comprising closed-ended questions, the scale consists of the following subdimensions: general health, physical, social, environmental, and psychological. The minimum score that can be obtained from the scale is 0, and the maximum score is 100. An increase in the score indicates an improvement in quality of life.

    Time frame: Before intervention

  2. After intervention

    Post-Intervention Life Satisfaction This scale was developed to assess how an individual perceives their quality of life. The scale was created by condensing the World Health Organization Quality of Life Assessment scale to 26 questions. During the validity studies of the Turkish version, a national question was added, bringing the total number of questions to 27, and the Turkish version was finalized. Comprising closed-ended questions, the scale consists of the following subdimensions: general health, physical, social, environmental, and psychological. The minimum score that can be obtained from the scale is 0, and the maximum score is 100. An increase in the score indicates an improvement in quality of life.

    Time frame: 1 week after intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.

Of 285 non-industry interventional studies with no phase under Caregiver Burden, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 2 months is below that.

Counting every sponsor, half of 294 studies reached it within 16 months; a quarter within 7 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Jul 2026 → Dec 2026, primary completion Aug 2026 → Feb 2027 and completion Aug 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
Jun 26, 2026
StartEst.
Dec 2026was Jul 2026
Primary completionEst.
Feb 2027was Aug 2026
CompletionEst.
Mar 2027was Aug 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Dec 2026
Nov 2, 2026
Primary completion
Aug 2026→Feb 2027
Nov 2, 2026
Study completion
Aug 2026→Mar 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Jul 2026→Dec 2026
    Primary completion Aug 2026→Feb 2027
    Study completion Aug 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07672340
Responsible party
Dilek Hassoy (PhD student, Aydin Adnan Menderes University) — Principal investigator
First posted
Jun 26, 2026
Start date
Dec 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Dilek Hassoy
Contact
dihassoy09@gmail.com
+905054829071
Safiye Özvurmaz, professor
Contact
sozvurmaz@hotmail.com
+90 5374746531

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion